School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Department of Orthopaedic Surgery, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas, USA.
Yale J Biol Med. 2024 Sep 30;97(3):399-413. doi: 10.59249/TKNM3388. eCollection 2024 Sep.
: The musculoskeletal system, due to inherent structure and function, lends itself to contributing toward joint pain, whether from inflammatory disorders such as rheumatoid arthritis, degenerative diseases such as osteoarthritis, or trauma causing soft tissue injury. Administration of peptides for treatment of joint pain or inflammation is an emerging line of therapy that seeks to offer therapeutic benefits while remaining safe and relatively non-invasive. : The purpose of this study is to review the current literature on existing oral peptide agents, intra-articular peptide agents, and new developments in human trials to assess route of administration (RoA) for drug delivery in terms of soft tissue regeneration. : Narrative Review. : A comprehensive literature search was conducted using the PubMed database. The search included medical subject headings (MeSH) terms related to peptide therapy, soft tissue regeneration, and RoA. Inclusion criteria comprised articles focusing on the mechanisms of action of peptides, clinical or biochemical outcomes, and review articles. Exclusion criteria included insufficient literature or studies not meeting the set evidence level. : The review identified various peptides demonstrating efficacy in soft tissue repair. Oral and intra-articular peptides showed distinct advantages in soft tissue regeneration, with intra-articular routes providing localized effects and oral routes offering systemic benefits. However, both routes have limitations in bioavailability and absorption. Still in their infancy, further inquiries/research into the properties and efficacy of emerging peptides will be necessary before widespread use. As a viable alternative prior to surgical intervention, peptide treatments present as promising candidates for positive outcomes in soft tissue regeneration.
骨骼肌肉系统由于其固有结构和功能,容易导致关节疼痛,无论是由类风湿性关节炎等炎症性疾病、骨关节炎等退行性疾病还是软组织损伤引起的创伤。肽类药物用于治疗关节疼痛或炎症是一种新兴的治疗方法,旨在提供治疗益处的同时保持安全和相对非侵入性。本研究旨在综述现有口服肽类药物、关节内肽类药物以及临床试验中的新进展,以评估药物输送的给药途径(RoA)在软组织再生方面的效果。
综述。
通过 PubMed 数据库进行了全面的文献检索。检索包括与肽治疗、软组织再生和 RoA 相关的医学主题词 (MeSH) 术语。纳入标准包括专注于肽作用机制、临床或生化结果的文章以及综述文章。排除标准包括文献不足或不符合既定证据水平的研究。
该综述确定了各种在软组织修复中显示出疗效的肽。口服和关节内肽在软组织再生方面表现出明显的优势,关节内途径提供局部作用,口服途径提供全身益处。然而,这两种途径在生物利用度和吸收方面都存在局限性。
在广泛应用之前,还需要进一步研究新兴肽的性质和功效,因为它们还处于起步阶段。作为手术干预前的可行替代方案,肽治疗为软组织再生带来了积极结果的有希望的候选药物。
Yale J Biol Med. 2024-9
Cochrane Database Syst Rev. 2022-2-1
Ont Health Technol Assess Ser. 2005
Ont Health Technol Assess Ser. 2005
Crit Rev Toxicol. 2024-9
Zhongguo Gu Shang. 2018-6-25
Tissue Eng Part B Rev. 2022-8
J Orthop Surg Res. 2023-9-16
Int Immunopharmacol. 2023-2